Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  EXACT Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/12/2019 07/15/2019 07/16/2019 07/17/2019 07/18/2019 Date
114.87(c) 116.19(c) 114.95(c) 116.34(c) 116.9(c) Last
1 668 068 1 111 188 930 136 842 953 794 502 Volume
-1.11% +1.15% -1.07% +1.21% +0.48% Change
More quotes
Financials (USD)
Sales 2019 747 M
EBIT 2019 -240 M
Net income 2019 -282 M
Finance 2019 195 M
Yield 2019 -
Sales 2020 1 086 M
EBIT 2020 -123 M
Net income 2020 -158 M
Finance 2020 112 M
Yield 2020 -
P/E ratio 2019 -53,0x
P/E ratio 2020 -101x
EV / Sales2019 19,9x
EV / Sales2020 13,8x
Capitalization 15 096 M
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based... 
Sector
Biotechnology & Medical Research
Calendar
07/25 | 11:00amShareholder meeting
More about the company
Surperformance© ratings of EXACT Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on EXACT SCIENCES CORPORATION
07/09EXACT SCIENCES : to host annual meeting, second-quarter 2019 results webcasts an..
PU
06/26EXACT SCIENCES : Advances Fight Against Colorectal Cancer With Opening Of New La..
PU
06/24EXACT SCIENCES : EMET Prize announces new cadre of winners
AQ
06/18EXACT SCIENCES : WEDC determines Exact Sciences doesn't owe anything
AQ
05/31EXACT SCIENCES : to participate in June investor conferences
PU
05/20EXACT SCIENCES : Advances Pipeline Capabilities with Mayo Clinic
PU
05/17EXACT SCIENCES : Presents New Data Reinforcing Performance of Cologuard®
PU
05/03EXACT SCIENCES : starts to see payoff from Pfizer marketing tie-up
AQ
05/01EXACT SCIENCES : to participate in May investor conferences
PU
04/30EXACT SCIENCES : 1Q Earnings Snapshot
AQ
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
07/17GILEAD SCIENCES : Chief Scientific Officer John McHutchison to Leave
DJ
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
More sector news : Biotechnology & Medical Research - NEC
Chart EXACT SCIENCES CORPORATION
Duration : Period :
EXACT Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 121,90  $
Last Close Price 116,90  $
Spread / Highest target 19,8%
Spread / Average Target 4,28%
Spread / Lowest Target -8,47%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey T. Elliott Chief Financial Officer
Barry M. Berger Co-Chief Medical Officer & Head-Medical Affairs
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION84.37%15 096
IQVIA HOLDINGS INC34.30%30 773
LONZA GROUP32.08%25 288
CELLTRION, INC.--.--%19 958
INCYTE CORPORATION27.87%17 204
SEATTLE GENETICS, INC.35.26%12 157